Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SHE:300357)

SHE:300357 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	1,045	921.46	840.75	894.88	804.12	633.42
Other Revenue	3.94	3.94	7.44	1.14	3.58	2.79
Revenue	1,049	925.39	848.19	896.02	807.69	636.21
Revenue Growth (YoY)	15.90%	9.10%	-5.34%	10.94%	26.95%	-0.49%
Cost of Revenue	49.65	44.81	40.19	42.51	34.44	28.54
Gross Profit	998.87	880.58	808	853.5	773.25	607.67
Selling, General & Admin	461.41	434.65	385.28	359.63	333.97	263.18
Research & Development	117.72	119.88	112.2	106.02	87.93	61.27
Other Operating Expenses	18.97	7.84	4.57	4.53	3.78	3.27
Operating Expenses	600.05	563.23	501.05	471.43	427.23	328.01
Operating Income	398.82	317.36	306.95	382.07	346.02	279.66
Interest Expense	-0.76	-1.06	-1.31	-0.44	-0.36	-
Interest & Investment Income	26.87	35.81	32.87	28.35	29.03	24.63
Currency Exchange Gain (Loss)	0	0	0	-0	-0	-0.01
Other Non Operating Income (Expenses)	2.44	-0.34	-0.26	-0.15	-0.17	-0.17
EBT Excluding Unusual Items	427.36	351.76	338.25	409.82	374.52	304.11
Gain (Loss) on Sale of Investments	4.82	2.43	-0.67	-0.88	-0.1	2.66
Gain (Loss) on Sale of Assets	0.63	0.57	-	-0.27	-	-
Asset Writedown	-1.42	-1.42	-0.58	-43.23	-0.1	-0.01
Other Unusual Items	14.41	11.72	8.95	33.3	18.67	15.85
Pretax Income	445.82	365.06	345.96	398.75	393	322.62
Income Tax Expense	68.74	60.72	50.43	63.02	66.71	52.89
Earnings From Continuing Operations	377.08	304.34	295.52	335.73	326.29	269.72
Minority Interest in Earnings	13.36	13.48	14.66	13.05	11.7	8.72
Net Income	390.43	317.82	310.18	348.77	337.99	278.45
Net Income to Common	390.43	317.82	310.18	348.77	337.99	278.45
Net Income Growth	25.02%	2.46%	-11.06%	3.19%	21.38%	-6.65%
Shares Outstanding (Basic)	524	524	524	524	524	524
Shares Outstanding (Diluted)	524	524	524	524	524	524
Shares Change (YoY)	-0.01%	-0.00%	-	-0.00%	0.00%	-0.00%
EPS (Basic)	0.75	0.61	0.59	0.67	0.65	0.53
EPS (Diluted)	0.75	0.61	0.59	0.67	0.65	0.53
EPS Growth	25.03%	2.46%	-11.06%	3.19%	21.38%	-6.65%
Free Cash Flow	246.92	133.12	154.61	159.62	236.33	186.06
Free Cash Flow Per Share	0.47	0.25	0.29	0.30	0.45	0.35
Dividend Per Share	0.120	0.220	0.185	0.200	0.201	0.160
Dividend Growth	-57.89%	18.92%	-7.50%	-0.50%	25.62%	-11.11%
Gross Margin	95.27%	95.16%	95.26%	95.25%	95.74%	95.51%
Operating Margin	38.04%	34.29%	36.19%	42.64%	42.84%	43.96%
Profit Margin	37.24%	34.34%	36.57%	38.92%	41.85%	43.77%
Free Cash Flow Margin	23.55%	14.39%	18.23%	17.82%	29.26%	29.25%
EBITDA	451.29	360.81	338.38	402.44	366.11	294.68
EBITDA Margin	43.04%	38.99%	39.89%	44.91%	45.33%	46.32%
D&A For EBITDA	52.47	43.45	31.43	20.37	20.08	15.03
EBIT	398.82	317.36	306.95	382.07	346.02	279.66
EBIT Margin	38.04%	34.29%	36.19%	42.64%	42.84%	43.96%
Effective Tax Rate	15.42%	16.63%	14.58%	15.80%	16.97%	16.39%
Revenue as Reported	1,049	925.39	848.19	896.02	807.69	636.21

Source: S&P Global Market Intelligence. Standard template. Financial Sources.